News | | More »

Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October

Press Release

Redeye interview with CEO Helén Tuvesson (in Swedish)

Equity research and Presentations

Active Biotech Interim Report Q2 2025

Press Release

Aktiespararna: Active Biotech: Lovande data i LION (in Swedish)

Equity research and Presentations

Active Biotech provides status update of its development programs

Press Release

Interview with investigators of laquinimod eye drop study LION now available on Active Biotech’s website

Press Release

Active Biotech reports study results with tasquinimod in heavily pre-treated patients with relapsed refractory multiple myeloma

Press Release

Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe

Press Release

Active Biotech reports positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye

Press Release

Interview with Lucia Masarova, Assistant Professor at MD Anderson Cancer Center

Equity research and Presentations

First patient dosed in the phase II study of tasquinimod in myelofibrosis in the US

Press Release

First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis

Press Release

Nasdaq Stockholm
ACTI
Financial Reports
Analyses and Presentations

Investor Relations

Tasquinimod
Laquinimod
Naptumomab

Projects

Annual Report 2024

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in hematological cancers, non-infectious uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Financial Calendar

Interim Report Jan-Sep 2025
Date: November 6, 2025

Events

No events are found.

Pipeline

Fully owned projects

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Hematological malignancies
Tasquinimod Multiple myeloma*
Tasquinimod Myelofibrosis
Tasquinimod Myelofibrosis
Inflammatory eye disorders
Laquinimod eye drops, safety and tolerability
Laquinimod eye drops, ocular biodistribution
Study ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Licensed projects

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod